Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

LENZ Therapeutics, Inc. (NASDAQ:LENZ) saw its stock rise 6.1% in premarket trading following the release of its second-quarter financial report and confirmation that the FDA’s decision on its New Drug ...

On Thursday, LENZ Therapeutics LENZ earned a positive adjustment to its Relative Strength (RS) Rating, from 89 to 92. Please watch the video at Investors.com - Find Top Growth Stocks With The IBD ...

LENZ Therapeutics Inc LENZ shares are trading higher by 2.6% to $28.72 during Monday’s session, though off their new 52-week high of $31.00, after the company announced the FDA accepted its new ...

“LENZ Therapeutics is strongly positioned with Phase 3 lead program, addressing a very large target market with near-term, high potential, value-inflecting milestones and a well-credentialed ...

LENZ Therapeutics continues to make strong progress in its U.S. commercial preparations for LNZ100, its investigational treatment for presbyopia, as the Company approaches the August 8, 2025 PDUFA ...

LENZ Therapeutics’ product candidate addresses a widespread condition affecting approximately 1.8 billion people globally, highlighting the potential market size and opportunity for the company.

Lenz Therapeutics said on Wednesday its lead experimental drug being tested in patients with a common age-related eye disorder showed improvement in nearsightedness in a late-stage study.

LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients ...

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 Provided by GlobeNewswire Mar 11, 2025, 12:00:00 PM ...